Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
Public ClinicalTrials.gov record NCT06615596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation: DESTINATION Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF). Current guidelines recommend continued anticoagulation based on stroke risk scores, even post-ablation, potentially exposing patients to unnecessary bleeding risks. This international, multicenter, randomized controlled trial aims to compare thromboembolic and bleeding event risks between patients who continue and discontinue anticoagulation after ablation. The study involves 3,160 AF patients, all free of AF recurrence within 6 months to 1 year after ablation. Smart wearable monitors will track recurrence, and patients are followed for 24 months to assess event rates. Findings may reshape anticoagulation guidelines, improving clinical practice for AF patients worldwide.
Study identification
- NCT ID
- NCT06615596
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 3,160 participants
Conditions and interventions
Conditions
Interventions
- discontinue anticoagulation therapy Behavioral
- Anticoagulant drugs Drug
- Catheter Ablation Procedure
Behavioral · Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2025
- Primary completion
- Dec 31, 2028
- Completion
- Dec 30, 2029
- Last update posted
- Jun 3, 2026
2025 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women Hospital | Boston | Massachusetts | 02115 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
Recently updated Atrial Fibrillation (AF) trials
Other public records listing Atrial Fibrillation (AF). Sorted by last update posted; newest first. Not a recommendation.
- NCT07626411: Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation Recruiting
- NCT07779213: Detection of Atrial Fibrillation Using PPG From Smartphone Cameras Recruiting
- NCT06707688: Abbott Medical - VERITAS Study Active, not recruiting
- NCT07711327: Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Not yet recruiting
- NCT07620262: Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study Recruiting
- NCT07705425: EPX-HTG for Structural Heart Procedures Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06615596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06615596 live on ClinicalTrials.gov.